Overview

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Status:
Recruiting
Trial end date:
2024-04-16
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab
Ustekinumab